Clinical significance of circulating biomarkers of immune-checkpoint molecules with atezolizumab plus bevacizumab therapy in unresectable hepatocellular carcinoma

Makoto Chuma(Yokohama City University Medical Center), Shin Maeda(University of Tokyo Hospital), Hidenori Toyoda(Ogaki Municipal Hospital), Makoto Sugimori(Yokohama City University Medical Center), Kazushi Numata(Yokohama City University Medical Center), Satoshi Yasuda(Tohoku University), Yusuke Mishima(Tokai University), Atsushi Hiraoka(Ehime Prefectural Central Hospital), Takashi Kumada(Gifu Kyoritsu University), Tomomi Okubo(Nippon Medical School), Shuichiro Iwasaki(Kitasato University), Chika Kusano(Kitasato University), Kota Tsuruya(Tokai University), Toshifumi Tada(Himeji Red Cross Hospital), Akito Nozaki(Yokohama City University Medical Center), Tatehiro Kagawa(Tokai University), Masanori Atsukawa(Nippon Medical School), Yuichi Koshiyama(Ogaki Municipal Hospital), Haruki Uojima(National Center for Global Health and Medicine), Yuki Miura(Japanese Red Cross Hadano Hospital), Manabu Morimoto(Kanagawa Prefectural Hospital Organization), Chikako Tokoro, Norio Itokawa(Chiba Hokusou Hospital), Yoshitake Arase(Tokai University), Hisashi Hidaka(Kitasato University)
Hepatology International
July 4, 2024
Cited by 11


Related Papers